Synthetic vehicles for DNA vaccination

Journal of Drug Targeting

Volumn 18, Issue 1, 2010, Pages 1-14

  Van Den Berg, Joost H ^a,b,c   Nuijen, Bastiaan ^a   Schumacher, Ton N ^c   Haanen, John B A G ^c   Storm, Gert ^b   Beijnen, Jos H ^a,b   Hennink, Wim E ^b  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

DNA vaccination; Nanoparticles; PEGylation; Plasmid DNA; Targeting

Indexed keywords

ADJUVANT; DNA VACCINE; DRUG VEHICLE; ENDONUCLEASE; LIPID;

ANTIGEN PRESENTING CELL; CELLULAR IMMUNITY; DNA IMMUNIZATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MECHANISM; DRUG UPTAKE; HUMAN; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; REVIEW; TARGET CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; PARTICLE SIZE; VACCINES, DNA;

EID: 72749117664     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/10611860903278023     Document Type: Review

References (125)

1. Bahloul C, Taieb D, Diouani MF, Ahmed SB, Chtourou Y, B'chir BI, Kharmachi H, Dellagi K. (2006). Field trials of a very potent rabies DNA vaccine which induced long lasting virus neutralizing antibodies and protection in dogs in experimental conditions. Vaccine, 24: 1063-1072.
2. Barry ME, Pinto-Gonzalez D, Orson FM, McKenzie GJ, Petry GR, Barry MA. (1999). Role of endogenous endonucleases and tissue site in transfection and CpG-mediated immune activation after naked DNA injection. Hum Gene Ther, 10: 2461-2480.
3. Bins AD, Jorritsma A, Wolkers MC, Hung CF, Wu TC, Schumacher TN, Haanen JB. (2005). A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nat Med, 11: 899-904.
4. Bins AD, Wolkers MC, van den Boom MD, Haanen JB, Schumacher TN. (2007). In vivo antigen stability affects DNA vaccine immunogenicity. J Immunol, 179: 2126-2133.
5. Birchall J, Coulman S, Pearton M, Allender C, Brain K, Anstey A, Gateley C, Wilke N, Morrissey A. (2005). Cutaneous DNA delivery and gene expression in ex vivo human skin explants via wet-etch micro-fabricated micro-needles. J Drug Target, 13: 415-421.
6. Bureau MF, Naimi S, Torero IR, Seguin J, Georger C, Arnould E, Maton L, Blanche F, Delaere P, Scherman D. (2004). Intramuscular plasmid DNA electrotransfer: Biodistribution and degradation. Biochim Biophys Acta, 1676: 138-148.
7. Calarota SA, Weiner DB, Lori F, Lisziewicz J. (2007). Induction of HIVspecific memory T-cell responses by topical DermaVir vaccine. Vaccine, 25: 3070-3074.
8. Cherng JY, van de Wetering P, Talsma H, Crommelin DJ, Hennink WE. (1997). Freeze-drying of poly((2-dimethylamino)ethyl methacrylate)-based gene delivery systems. Pharm Res, 14: 1838-1841.
9. Christensen D, Korsholm KS, Rosenkrands I, Lindenstrom T, Andersen P, Agger EM. (2007). Cationic liposomes as vaccine adjuvants. Expert Rev Vaccines, 6: 785-796.
10. Cohen H, Levy RJ, Gao J, Fishbein I, Kousaev V, Sosnowski S, Slomkowski S, Golomb G. (2000). Sustained delivery and expression of DNA encapsulated in polymeric nanoparticles. Gene Ther, 7: 1896-1905.
11. Crook K, McLachlan G, Stevenson BJ, Porteous DJ. (1996). Plasmid DNA molecules complexed with cationic liposomes are protected from degradation by nucleases and shearing by aerosolisation. Gene Ther, 3: 834-839.
12. De Smedt SC, Demeester J, Hennink WE. (2000). Cationic polymer based gene delivery systems. Pharm Res, 17: 113-126.
13. de Wolf HK, Luten J, Snel CJ, Oussoren C, Hennink WE, Storm G. (2005). In vivo tumor transfection mediated by polyplexes based on biodegradable poly(DMAEA)-phosphazene. J Control Release, 109: 275-287.
14. El Aneed A. (2004). An overview of current delivery systems in cancer gene therapy. J Control Release, 94: 1-14.
15. Felgner PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz M, Northrop JP, Ringold GM, Danielsen M. (1987). Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci U S A, 84: 7413-7417.
16. Foged C, Brodin B, Frokjaer S, Sundblad A. (2005). Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. Int J Pharm, 298: 315-322.
17. Fu TM, Ulmer JB, Caulfield MJ, Deck RR, Friedman A, Wang S, Liu X, Donnelly JJ, Liu MA. (1997). Priming of cytotoxic T lymphocytes by DNA vaccines: Requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes. Mol Med, 3: 362-371.
18. Funhoff AM, van Nostrum CF, Janssen AP, Fens MH, Crommelin DJ, Hennink WE. (2004). Polymer side-chain degradation as a tool to control the destabilization of polyplexes. Pharm Res, 21: 170-176.
19. Galanis E, Hersh EM, Stopeck AT, Gonzalez R, Burch P, Spier C, Akporiaye ET, Rinehart JJ, Edmonson J, Sobol RE, Forscher C, Sondak VK, Lewis BD, Unger EC, O'Driscoll M, Selk L, Rubin J. (1999). Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: Phase I/II experience. J Clin Oncol, 17: 3313-3323.
20. Garzon MR, Berraondo P, Crettaz J, Ochoa L, Vera M, Lasarte JJ, Vales A, van Rooijen N, Ruiz J, Prieto J, Zulueta J, Gonzalez- Aseguinolaza G. (2005). Induction of gp120-specific protective immune responses by genetic vaccination with linear polyethylenimine- plasmid complex. Vaccine, 23: 1384-1392.
21. Gaumet M, Gurny R, Delie F. (2009). Localization and quantification of biodegradable particles in an intestinal cell model: The influence of particle size. Eur J Pharm Sci, 36: 465-473.
22. Gieseler RK, Marquitan G, Hahn MJ, Perdon LA, Driessen WH, Sullivan SM, Scolaro MJ. (2004). DC-SIGN-specific liposomal targeting and selective intracellular compound delivery to human myeloid dendritic cells: Implications for HIV disease. Scand J Immunol, 59: 415-424.
23. Gleich LL, Gluckman JL, Nemunaitis J, Suen JY, Hanna E, Wolf GT, Coltrera MD, Villaret DB, Wagman L, Castro D, Gapany M, Carroll W, Gillespie D, Selk LM. (2001). Clinical experience with HLA-B7 plasmid DNA/lipid complex in advanced squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg, 127: 775-779.
24. Goh SL, Murthy N, Xu M, Frechet JM. (2004). Cross-linked microparticles as carriers for the delivery of plasmid DNA for vaccine development. Bioconjug Chem, 15: 467-474.
25. Hattori Y, Kawakami S, Lu Y, Nakamura K, Yamashita F, Hashida M. (2006a). Enhanced DNA vaccine potency by mannosylated lipoplex after intraperitoneal administration. J Gene Med, 8: 824-834.
26. Hattori Y, Kawakami S, Nakamura K, Yamashita F, Hashida M. (2006b). Efficient gene transfer into macrophages and dendritic cells by in vivo gene delivery with mannosylated lipoplex via the intraperitoneal route. J Pharmacol Exp Ther, 318: 828-834.
27. Haynes JR. (2004). Particle-mediated DNA vaccine delivery to the skin. Expert Opin Biol Ther, 4: 889-900.
28. Hedley ML, Curley J, Urban R. (1998). Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses. Nat Med, 4: 365-368.
29. Heller LC, Jaroszeski MJ, Coppola D, McCray AN, Hickey J, Heller R. (2007). Optimization of cutaneous electrically mediated plasmid DNA delivery using novel electrode. Gene Ther, 14: 275-280.
30. Hinrichs WL, Mancenido FA, Sanders NN, Braeckmans K, De Smedt SC, Demeester J, Frijlink HW. (2006). The choice of a suitable oligosaccharide to prevent aggregation of PEGylated nanoparticles during freeze thawing and freeze drying. Int J Pharm, 311: 237-244.
31. Houk BE, Hochhaus G, Hughes JA. (1999). Kinetic modeling of plasmid DNA degradation in rat plasma. AAPS PharmSci, 1: E9.
32. Houk BE, Martin R, Hochhaus G, Hughes JA. (2001). Pharmacokinetics of plasmid DNA in the rat. Pharm Res, 18: 67-74.
33. Howard KA, Alpar HO. (2002). The development of polyplex-based DNA vaccines. J Drug Target, 10: 143-151.
34. Hsu KF, Hung CF, Cheng WF, He L, Slater LA, Ling M, Wu TC. (2001). Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen. Gene Ther, 8: 376-383.
35. Hui KM, Ang PT, Huang L, Tay SK. (1997). Phase I study of immunotherapy of cutaneous metastases of human carcinoma using allogeneic and xenogeneic MHC DNA-liposome complexes. Gene Ther, 4: 783-790.
36. Jechlinger W. (2006). Optimization and delivery of plasmid DNA for vaccination. Expert Rev Vaccines, 5: 803-825.
37. Jiao X, Wang RY, Feng Z, Alter HJ, Shih JW. (2003). Modulation of cellular immune response against hepatitis C virus nonstructural protein 3 by cationic liposome encapsulated DNA immunization. Hepatology, 37: 452-460.
38. Jilek S, Merkle HP, Walter E. (2005). DNA-loaded biodegradable microparticles as vaccine delivery systems and their interaction with dendritic cells. Adv Drug Deliv Rev, 57: 377-390.
39. Jilek S, Ulrich M, Merkle HP, Walter E. (2004). Composition and surface charge of DNA-loaded microparticles determine maturation and cytokine secretion in human dendritic cells. Pharm Res, 21: 1240-1247.
40. Johnston D, Bystryn JC. (2006). Topical imiquimod is a potent adjuvant to a weakly-immunogenic protein prototype vaccine. Vaccine, 24: 1958-1965.
41. Jones S, Evans K, McElwaine-Johnn H, Sharpe M, Oxford J, Lambkin- Williams R, Mant T, Nolan A, Zambon M, Ellis J, Beadle J, Loudon PT. (2009). DNA vaccination protects against an influenza challenge in a double-blind randomised placebo- controlled phase 1b clinical trial. Vaccine, 27: 2506-2512.
42. Kawase A, Isaji K, Yamaoka A, Kobayashi N, Nishikawa M, Takakura Y. (2006). Enhanced antigen-specific antibody production following polyplex-based DNA vaccination via the intradermal route in mice. Vaccine, 24: 5535-5545.
43. Klencke B, Matijevic M, Urban RG, Lathey JL, Hedley ML, Berry M, Thatcher J, Weinberg V, Wilson J, Darragh T, Jay N, Da Costa M, Palefsky JM. (2002). Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: A Phase I study of ZYC101. Clin Cancer Res, 8: 1028-1037.
44. Klinman DM, Sechler JM, Conover J, Gu M, Rosenberg AS. (1998). Contribution of cells at the site of DNA vaccination to the generation of antigen-specific immunity and memory. J Immunol, 160: 2388-2392.
45. Lappalainen K, Jaaskelainen I, Syrjanen K, Urtti A, Syrjanen S. (1994). Comparison of cell proliferation and toxicity assays using two cationic liposomes. Pharm Res, 11: 1127-1131.
46. Larsen CP, Steinman RM, Witmer-Pack M, Hankins DF, Morris PJ, Austyn JM. (1990). Migration and maturation of Langerhans cells in skin transplants and explants. J Exp Med, 172: 1483-1493.
47. Lee M, Kim SW. (2005). Polyethylene glycol-conjugated copolymers for plasmid DNA delivery. Pharm Res, 22: 1-10.
48. Lin C, Engbersen JF. (2008). Effect of chemical functionalities in poly(amido amine)s for non-viral gene transfection. J Control Release, 132: 267-272.
49. Lisziewicz J, Trocio J, Whitman L, Varga G, Xu J, Bakare N, Erbacher P, Fox C, Woodward R, Markham P, Arya S, Behr JP, Lori F. (2005). DermaVir: A novel topical vaccine for HIV/AIDS. J Invest Dermatol, 124: 160-169.
50. Lisziewicz J, Kelly L, Lori F. (2006). Topical DermaVir vaccine targeting dendritic cells. Curr Drug Deliv, 3: 83-88.
51. Little SR, Lynn DM, Ge Q, Anderson DG, Puram SV, Chen J, Eisen HN, Langer R. (2004). Poly-beta amino ester-containing microparticles enhance the activity of nonviral genetic vaccines. Proc Natl Acad Sci U S A, 101: 9534-9539.
52. Liu MA, Ulmer JB. (2005). Human clinical trials of plasmid DNA vaccines. Adv Genet, 55: 25-40.
53. Lodmell DL, Ray NB, Ulrich JT, Ewalt LC. (2000). DNA vaccination of mice against rabies virus: Effects of the route of vaccination and the adjuvant monophosphoryl lipid A (MPL). Vaccine, 18: 1059-1066.
54. Lou PJ, Cheng WF, Chung YC, Cheng CY, Chiu LH, Young TH. (2009). PMMA particle-mediated DNA vaccine for cervical cancer. J Biomed Mater Res A, 88: 849-857.
55. Louise C. (2006). Nonviral vectors. Methods Mol Biol, 333: 201-226.
56. Lu Y, Kawakami S, Yamashita F, Hashida M. (2007). Development of an antigen-presenting cell-targeted DNA vaccine against melanoma by mannosylated liposomes. Biomaterials, 28: 3255-3262.
57. Luby TM, Cole G, Baker L, Kornher JS, Ramstedt U, Hedley ML. (2004). Repeated immunization with plasmid DNA formulated in poly(lactide-co-glycolide) microparticles is well tolerated and stimulates durable T cell responses to the tumor-associated antigen cytochrome P450 1B1. Clin Immunol, 112: 45-53.
58. Lungwitz U, Breunig M, Blunk T, Gopferich A. (2005). Polyethylenimine- based non-viral gene delivery systems. Eur J Pharm Biopharm, 60: 247-266.
59. Luo Y, O'hagan D, Zhou H, Singh M, Ulmer J, Reisfeld RA, James PF, Xiang R. (2003). Plasmid DNA encoding human carcinoembryonic antigen (CEA) adsorbed onto cationic microparticles induces protective immunity against colon cancer in CEAtransgenic mice. Vaccine, 21: 1938-1947.
60. Luten J, van Nostrum CF, De Smedt SC, Hennink WE. (2008). Biodegradable polymers as non-viral carriers for plasmid DNA delivery. J Control Release, 126: 97-110.
61. Lv H, Zhang S, Wang B, Cui S, Yan J. (2006). Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release, 114: 100-109.
62. Maruyama H, Miyazaki J, Gejyo F. (2005). Epidermis-targeted gene transfer using in vivo electroporation. Methods Mol Biol, 289: 431-436.
63. Melief CJ. (2003). Mini-review: Regulation of cytotoxic T lymphocyte responses by dendritic cells: Peaceful coexistence of cross-priming and direct priming? Eur J Immunol, 33: 2645-2654.
64. Minigo G, Scholzen A, Tang CK, Hanley JC, Kalkanidis M, Pietersz GA, Apostolopoulos V, Plebanski M. (2007). Poly-l-lysine-coated nanoparticles: A potent delivery system to enhance DNA vaccine efficacy. Vaccine, 25: 1316-1327.
65. Mislick KA, Baldeschwieler JD. (1996). Evidence for the role of proteoglycans in cation-mediated gene transfer. Proc Natl Acad Sci U S A, 93: 12349-12354.
66. Mitragotri S. (2005). Immunization without needles. Nat Rev Immunol, 5: 905-916.
67. Morille M, Passirani C, Vonarbourg A, Clavreul A, Benoit JP. (2008). Progress in developing cationic vectors for non-viral systemic gene therapy against cancer. Biomaterials, 29: 3477-3496.
68. Nabel GJ, Gordon D, Bishop DK, Nickoloff BJ, Yang ZY, Aruga A, Cameron MJ, Nabel EG, Chang AE. (1996). Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc Natl Acad Sci U S A, 93: 15388-15393.
69. Nchinda G, Kuroiwa J, Oks M, Trumpfheller C, Park CG, Huang Y, Hannaman D, Schlesinger SJ, Mizenina O, Nussenzweig MC, Uberla K, Steinman RM. (2008). The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells. J Clin Invest, 118: 1427-1436.
70. Newman KD, Elamanchili P, Kwon GS, Samuel J. (2002). Uptake of poly(d,l-lactic-co-glycolic acid) microspheres by antigen- presenting cells in vivo. J Biomed Mater Res, 60: 480-486.
71. Oster CG, Kim N, Grode L, Barbu-Tudoran L, Schaper AK, Kaufmann SH, Kissel T. (2005). Cationic microparticles consisting of poly(lactide-co- glycolide) and polyethylenimine as carriers systems for parental DNA vaccination. J Control Release, 104: 359-377.
72. Pai KS, Qin H, Thomson KS, El Bereir S, Cha SC, Neelapu S, Kwak LW, Roy K. (2006). Prophylactic anti-tumor effects in a B cell lymphoma model with DNA vaccines delivered on polyethylenimine (PEI) functionalized PLGA microparticles. J Control Release, 113: 261-270.
73. Patil SD, Rhodes DG, Burgess DJ. (2005). DNA-based therapeutics and DNA delivery systems: A comprehensive review. AAPS J, 7: E61-E77.
74. Peng B, Zhao Y, Xu L, Xu Y. (2007). Electric pulses applied prior to intramuscular DNA vaccination greatly improve the vaccine immunogenicity. Vaccine, 25: 2064-2073.
75. Peng S, Tomson TT, Trimble C, He L, Hung CF, Wu TC. (2006). A combination of DNA vaccines targeting human papillomavirus type 16 E6 and E7 generates potent antitumor effects. Gene Ther, 13: 257-265.
76. Pokorna D, Rubio I, Muller M. (2008). DNA-vaccination via tattooing induces stronger humoral and cellular immune responses than intramuscular delivery supported by molecular adjuvants. Genet Vaccines Ther, 6: 4.
77. Porteous DJ, Dorin JR, McLachlan G, Davidson-Smith H, Davidson H, Stevenson BJ, Carothers AD, Wallace WA, Moralee S, Hoenes C, Kallmeyer G, Michaelis U, Naujoks K, Ho LP, Samways JM, Imrie M, Greening AP, Innes JA. (1997). Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther, 4: 210-218.
78. Prabha S, Zhou WZ, Panyam J, Labhasetwar V. (2002). Sizedependency of nanoparticle-mediated gene transfection: Studies with fractionated nanoparticles. Int J Pharm, 244: 105-115.
79. Prud'homme GJ. (2005). DNA vaccination against tumors. J Gene Med, 7: 3-17.
80. Quaak SG, van den Berg JH, Toebes M, Schumacher TN, Haanen JB, Beijnen JH, Nuijen B. (2008). GMP production of pDERMATT for vaccination against melanoma in a phase I clinical trial. Eur J Pharm Biopharm, 70: 429-438.
81. Rejman J, Oberle V, Zuhorn IS, Hoekstra D. (2004). Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J, 377: 159-169.
82. Romberg B, Hennink WE, Storm G. (2008). Sheddable coatings for long-circulating nanoparticles. Pharm Res, 25: 55-71.
83. Roos AK, Moreno S, Leder C, Pavlenko M, King A, Pisa P. (2006). Enhancement of cellular immune response to a prostate cancer DNA vaccine by intradermal electroporation. Mol Ther, 13: 320-327.
84. Roques C, Fattal E, Fromes Y. (2009). Comparison of toxicity and transfection efficiency of amphiphilic block copolymers and polycationic polymers in striated muscles. J Gene Med, 11: 240-249.
85. Rosenberg SA, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, White DE. (2003). Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Hum Gene Ther, 14: 709-714.
86. Ruponen M, Yla-Herttuala S, Urtti A. (1999). Interactions of polymeric and liposomal gene delivery systems with extracellular glycosaminoglycans: Physicochemical and transfection studies. Biochim Biophys Acta, 1415: 331-341.
87. Ruponen M, Ronkko S, Honkakoski P, Pelkonen J, Tammi M, Urtti A. (2001). Extracellular glycosaminoglycans modify cellular trafficking of lipoplexes and polyplexes. J Biol Chem, 276: 33875-33880.
88. Ruponen M, Honkakoski P, Tammi M, Urtti A. (2004). Cell-surface glycosaminoglycans inhibit cation-mediated gene transfer. J Gene Med, 6: 405-414.
89. Sheets EE, Urban RG, Crum CP, Hedley ML, Politch JA, Gold MA, Muderspach LI, Cole GA, Crowley-Nowick PA. (2003). Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA. Am J Obstet Gynecol, 188: 916-926.
90. Singh M, Briones M, Ott G, O'hagan D. (2000). Cationic microparticles: A potent delivery system for DNA vaccines. Proc Natl Acad Sci U S A, 97: 811-816.
91. Sloots A, Mastini C, Rohrbach F, Weth R, Curcio C, Burkhardt U, Jager E, Forni G, Cavallo F, Wels WS. (2008). DNA vaccines targeting tumor antigens to B7 molecules on antigen-presenting cells induce protective antitumor immunity and delay onset of HER-2/Neu-driven mammary carcinoma. Clin Cancer Res, 14: 6933-6943.
92. Song YK, Liu F, Liu D. (1998). Enhanced gene expression in mouse lung by prolonging the retention time of intravenously injected plasmid DNA. Gene Ther, 5: 1531-1537.
93. Spagnoli GC, Adamina M, Bolli M, Weber WP, Zajac P, Marti W, Oertli D, Heberer M, Harder F. (2005). Active antigen-specific immunotherapy of melanoma: From basic science to clinical investigation. World J Surg, 29: 692-699.
94. Steitz J, Britten CM, Wolfel T, Tuting T. (2006). Effective induction of anti-melanoma immunity following genetic vaccination with synthetic mRNA coding for the fusion protein EGFP.TRP2. Cancer Immunol Immunother, 55: 246-253.
95. Stern M, Ulrich K, Geddes DM, Alton EW. (2003). Poly (d, l-lactideco- glycolide)/DNA microspheres to facilitate prolonged transgene expression in airway epithelium in vitro, ex vivo and in vivo. Gene Ther, 10: 1282-1288.
96. Stevenson FK, Ottensmeier CH, Johnson P, Zhu D, Buchan SL, McCann KJ, Roddick JS, King AT, McNicholl F, Savelyeva N, Rice J. (2004). DNA vaccines to attack cancer. Proc Natl Acad Sci U S A, 101(Suppl. 2): 14646-14652.
97. Thierry AR, Lunardi-Iskandar Y, Bryant JL, Rabinovich P, Gallo RC, Mahan LC. (1995). Systemic gene therapy: Biodistribution and long-term expression of a transgene in mice. Proc Natl Acad Sci U S A, 92: 9742-9746.
98. Thomsen LL, Topley P, Daly MG, Brett SJ, Tite JP. (2004). Imiquimod and resiquimod in a mouse model: Adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery. Vaccine, 22: 1799-1809.
99. + cervical intraepithelial neoplasia 2/3. Clin Cancer Res, 15: 361-367.
100. Trubetskoy VS, Loomis A, Hagstrom JE, Budker VG, Wolff JA. (1999). Layer-by-layer deposition of oppositely charged polyelectrolytes on the surface of condensed DNA particles. Nucleic Acids Res, 27: 3090-3095.
101. Trubetskoy VS, Wong SC, Subbotin V, Budker VG, Loomis A, Hagstrom JE, Wolff JA. (2003). Recharging cationic DNA complexes with highly charged polyanions for in vitro and in vivo gene delivery. Gene Ther, 10: 261-271.
102. Tuting T, Storkus WJ, Falo LD Jr. (1998). DNA immunization targeting the skin: Molecular control of adaptive immunity. J Invest Dermatol, 111: 183-188.
103. U'Ren L, Kedl R, Dow S. (2006). Vaccination with liposome-DNA complexes elicits enhanced antitumor immunity. Cancer Gene Ther, 13: 1033-1044.
104. Ulmer JB, Deck RR, Dewitt CM, Donnhly JI, Liu MA. (1996). Generation of MHC class I-restricted cytotoxic T lymphocytes by expression of a viral protein in muscle cells: Antigen presentation by non-muscle cells. Immunology, 89: 59-67.
105. van den Berg JH, Nujien B, Beijnen JH, Vincent A, Van Tinteren H, Kluge J, Woerdeman LA, Hennink WE, Storm G, Schumacher TN, Haanen JB. (2009a). Optimization of intradermal vaccination by DNA tattooing in human skin. Hum Gene Ther, 20: 181-189.
106. van den Berg JH, Oosterhuis K, Hennink WE, Storm G, van der Aa LJ, Engbersen JFJ, Haanen JBAG, Beijnen JH, Schumacher TN, Nuijen B. (2009b). Shielding the cationic charge of nanoparticle- formulated dermal DNA vaccines is essential for antigen expression and immunogenicity. J Control Release. In press.
107. van der Aa MA, Huth US, Hafele SY, Schubert R, Oosting RS, Mastrobattista E, Hennink WE, Peschka-Suss R, Koning GA, Crommelin DJ. (2007). Cellular uptake of cationic polymer-DNA complexes via caveolae plays a pivotal role in gene transfection in COS-7 cells. Pharm Res, 24: 1590-1598.
108. van der Aa MA, Koning GA, d'Oliveira C, Oosting RS, Wilschut KJ, Hennink WE, Crommelin DJ. (2005). An NLS peptide covalently linked to linear DNA does not enhance transfection efficiency of cationic polymer based gene delivery systems. J Gene Med, 7: 208-217.
109. van der Aa MA, Mastrobattista E, Oosting RS, Hennink WE, Koning GA, Crommelin DJ. (2006). The nuclear pore complex: The gateway to successful nonviral gene delivery. Pharm Res, 23: 447-459.
110. van Slooten ML, Storm G, Zoephel A, Kupcu Z, Boerman O, Crommelin DJ, Wagner E, Kircheis R. (2000). Liposomes containing interferon-gamma as adjuvant in tumor cell vaccines. Pharm Res, 17: 42-48.
111. van Slooten ML, Hayon I, Babai I, Zakay-Rones Z, Wagner E, Storm G, Kedar E. (2001). Immunoadjuvant activity of interferon-gammaliposomes co-administered with influenza vaccines. Biochim Biophys Acta, 1531: 99-110.
112. Vangasseri DP, Cui Z, Chen W, Hokey DA, Falo LD Jr, Huang L. (2006). Immunostimulation of dendritic cells by cationic liposomes. Mol Membr Biol, 23: 385-395.
113. Verstrepen BE, Bins AD, Rollier CS, Mooij P, Koopman G, Sheppard NC, Sattentau Q, Wagner R, Wolf H, Schumacher TN, Heeney JL, Haanen JB. (2008). Improved HIV-1 specific T-cell responses by short-interval DNA tattooing as compared to intramuscular immunization in non-human primates. Vaccine, 26: 3346-3351.
114. Vives E, Schmidt J, Pelegrin A. (2008). Cell-penetrating and cell- targeting peptides in drug delivery. Biochim Biophys Acta, 1786: 126-138.
115. Vyas JM, Van der Veen AG, Ploegh HL. (2008). The known unknowns of antigen processing and presentation. Nat Rev Immunol, 8: 607-618.
116. Wang D, Robinson DR, Kwon GS, Samuel J. (1999). Encapsulation of plasmid DNA in biodegradable poly(d, l-lactic-co-glycolic acid) microspheres as a novel approach for immunogene delivery. J Control Release, 57: 9-18.
117. Wattendorf U, Coullerez G, Voros J, Textor M, Merkle HP. (2008). Mannose-based molecular patterns on stealth microspheres for receptor-specific targeting of human antigen-presenting cells. Langmuir, 24: 11790-11802.
118. Wilson KD, de Jong SD, Kazem M, Lall R, Hope MJ, Cullis PR, Tam YK. (2009). The combination of stabilized plasmid lipid particles and lipid nanoparticle encapsulated CpG containing oligodeoxynucleotides as a systemic genetic vaccine. J Gene Med, 11: 14-25.
119. Wolkers MC, Toebes M, Okabe M, Haanen JB, Schumacher TN. (2002). Optimizing the efficacy of epitope-directed DNA vaccination. J Immunol, 168: 4998-5004.
120. Xiang SD, Scalzo-Inguanti K, Minigo G, Park A, Hardy CL, Plebanski M. (2008). Promising particle-based vaccines in cancer therapy. Expert Rev Vaccines, 7: 1103-1119.
121. Xu R, Megati S, Roopchand V, Luckay A, Masood A, Garcia-Hand D, Rosati M, Weiner DB, Felber BK, Pavlakis GN, Sidhu MK, Eldridge JH, Egan MA. (2008). Comparative ability of various plasmid-based cytokines and chemokines to adjuvant the activity of HIV plasmid DNA vaccines. Vaccine, 26: 4819-4829.
122. Xu ZL, Mizuguchi H, Ishii-Watabe A, Uchida E, Mayumi T, Hayakawa T. (2001). Optimization of transcriptional regulatory elements for constructing plasmid vectors. Gene, 272: 149-156.
123. Yan W, Chen W, Huang L. (2008). Reactive oxygen species play a central role in the activity of cationic liposome based cancer vaccine. J Control Release, 130: 22-28.
124. Zhang A, Jin H, Zhang F, Ma Z, Tu Y, Ren Z, Zhang X, Zhu K, Wang B. (2005). Effects of multiple copies of CpG on DNA vaccination. DNA Cell Biol, 24: 292-298.
125. Zhang S, Xu Y, Wang B, Qiao W, Liu D, Li Z. (2004). Cationic compounds used in lipoplexes and polyplexes for gene delivery. J Control Release, 100: 165-180.